The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESH MM 2018 | A novel mechanism of action for daratumumab in myeloma

Name: A novel mechanism of action for daratumumab in myeloma
Uploaded: 2018-10-05T00:00:00.000Z
Duration: 2 min 4 s
Description: The anti-CD38 antibody daratumumab, a success in multiple myeloma (MM), has pleiotropic mechanisms. Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses a novel mechanism of action for daratumumab, trogocytosis. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Niels van de Donk • 5 Oct 2018

ESH MM 2018

Multiple Myeloma Antibodies Daratumumab

The anti-CD38 antibody daratumumab, a success in multiple myeloma (MM), has pleiotropic mechanisms. Here, Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses a novel mechanism of action for daratumumab, trogocytosis. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.